Aerie pharmaceuticals, inc. completes enrollment in the phase 2 trial of ar-1105 (dexamethasone intravitreal implant) in patients with macular edema associated with retinal vein occlusion ahead of schedule
Aerie pharmaceuticals, inc. announced that patient enrollment in its phase 2 clinical trial of ar-1105 in patients with macular edema due to retinal vein occlusion (rvo) is complete several weeks ahead of schedule. ar-1105 is an investigational sustained-release, bio-erodible intravitreal implant containing dexamethasone. the phase 2 study (ar-1105-cs201), conducted at 19 centers in the united states, had an enrollment target of 45 patients. the trial is evaluating two formulations of ar-1105 (cf-1 and cf-2) that differ in the duration of dexamethasone release. a few additional patients are currently being screened and, if they are randomized, could bring the total number of patients in the final evaluation to a maximum of 49. the primary objectives of the trial are to evaluate the safety, tolerability and efficacy of the ar-1105 dexamethasone intravitreal implant. safety and efficacy will be evaluated at six months.
AERI Ratings Summary
AERI Quant Ranking
You've reached your free article limit.
Want To Read More Articles?
See what it all means for your stocks with premium tools
Stockprices is a weekly video covering what moved markets
this week, featuring a panel of Stockprices editors. It is published by the
close of trading on Fridays. Hosted by Nathaniel E. Baker, contributing editor,
and featuring: Aaron Task, VP Contributor Content and co-host Stockprices's Alpha
Trader podcast; Brad Olesen, VP News; Steve Alpher, Managing Editor News, co-host
Alpha Trader.
Unsubscribe From All
You successfully activated
“Only Essentials”
Confirm Upgrade
Your subscription will be moved to the annual plan. Service will automatically renew unless cancelled. No Refunds. Click upgrade to confirm.
Stockprices uses Plaid to connect you account
Connect effortlessly
Plaid lets you securely connect your financial accounts in seconds
Your data belongs to you
Plaid doesn't sell personal info, and will only use it with your permission